Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15318993 | 1.00 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL932564 | 1.00 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL28981240 | 0.98 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| Mercaptopropionic Acid SCHEMBL4955336 | 0.85 | PTGS1 (0.39) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL6047333 | 0.85 | KMT2A (0.42) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL15391718 | 0.82 | PTGS1 (0.51) | CSNK2A2CSNK2BCSNK2A1KDM4ELMNA | |
| SCHEMBL22241544 | 0.81 | LMNA (0.36) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL2611102 | 0.81 | LMNA (0.36) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL28844372 | 0.80 | TSHR (0.39) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 | |
| SCHEMBL321357 | 0.79 | LMNA (0.35) | CSNK2A2CSNK2BCSNK2A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243208-A2 | PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF | HOVIONE - FARMACIÊNCIA, SA (PT) | 2025-11-27 | — | — | WO | claimed |
| CN-119823209-A | Synthesis method of cyclic peptide containing maleimide acid | 江苏金斯瑞生物科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118290405-B | Fluorescent probe for targeting SLC7A5 high-expression tumor and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2025-02-28 | — | — | CN | claimed |
| CN-118725337-A | Hydroxyl-terminated hyperbranched polyester modified hindered phenol composite material and butyl rubber damping material prepared from same | 艾华(浙江)新材料有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118290405-A | Fluorescent probe for targeting SLC7A5 high-expression tumor and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2024-07-05 | — | — | CN | claimed |
| CN-117838877-A | Polypeptide P12-drug conjugate and application thereof in preparation of drugs for treating pancreatic cancer | 中国医学科学院基础医学研究所 | 2024-04-09 | — | — | CN | claimed |
| US-11793886-B2 | Hydrophilic linkers and conjugates thereof | GLYKOS FINLAND OY (FI) | 2023-10-24 | — | — | US | claimed |
| US-20230277612-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-07 | — | — | US | claimed |
| US-20230272008-A1 | NON-CLEAVABLE SUBSTANCE P CONJUGATES AND METHODS OF USE THEREOF | VEIOVE ANIMAL HEALTH INC. | 2023-08-31 | — | — | US | claimed |
| EP-4171642-A1 | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTIBODY-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| US-20030170250-A1 | Local delivery of long lasting therapeutic agents | EZRIN ALAN M (US) | 2003-09-11 | — | — | US | claimed |
| US-20020039999-A1 | Antinociceptive agent derivative | CONJUCHEM, LLC | 2002-04-04 | — | — | US | claimed |
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | CONJUCHEM, INC. (CA) | 2002-02-14 | — | — | US | claimed |
| US-20010018420-A1 | Method for alleviating pain or providing an analgesic effect in a patient | CONJUCHEM, LLC | 2001-08-30 | — | — | US | claimed |
| US-20010018421-A1 | Conjugate comprising an antinociceptive agent covalently bonded to a blood component | CONJUCHEM, LLC | 2001-08-30 | — | — | US | claimed |
| EP-1042003-A1 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | Conjuchem, Inc. (CA) | 2000-10-11 | — | — | EP | claimed |
| US-6107489-A | CHEMICALLY REACTIVE TRIPEPTIDE INTERMEDIATES WHICH CAN REACT WITH AVAILABLE REACTIVE FUNCTIONALITIES ON BLOOD COMPONENTS TO FORM COVALENT LINKAGES, THE RESULTING CONJUGATES HAVE RENIN INHIBITION ACTIVITY FOR EXTENDED PERIODS OF TIME | CONJUCHEM, INC. (CA) | 2000-08-22 | — | — | US | claimed |
| EP-1007561-A2 | NOVEL CONJUGATES OF OPIOIDS AND ENDOGENOUS CARRIERS | Conjuchem, Inc. (CA) | 2000-06-14 | — | — | EP | claimed |
| WO-1999048536-A2 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | CONJUCHEM, INC. (CA) | 1999-09-30 | — | — | WO | claimed |
| WO-1999024074-A2 | NOVEL CONJUGATES OF OPIOIDS AND ENDOGENOUS CARRIERS | CONJUCHEM, INC. (CA) | 1999-05-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018420-A1 | Method for alleviating pain or providing an analgesic effect in a patient | OPRK1, OPRL1, OGFR | CSNK2A2 2981/4885CSNK2B 3206/4885CSNK2A1 3129/4885 |
| US-20230277612-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | HAVCR2, HCCS, PYGL | CSNK2A2 2386/4885CSNK2B 2243/4885CSNK2A1 2316/4885 |
| US-11793886-B2 | Hydrophilic linkers and conjugates thereof | CD44, FOLR2, SLCO2B1 | CSNK2A2 3356/4885CSNK2B 3050/4885CSNK2A1 3737/4885 |
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | FABP3, VCAM1, TAGLN2 | CSNK2A2 3515/4885CSNK2B 3521/4885CSNK2A1 3759/4885 |
| US-20020039999-A1 | Antinociceptive agent derivative | OPRK1, OPRL1, OGFR | CSNK2A2 3031/4885CSNK2B 3341/4885CSNK2A1 3035/4885 |
| US-20010018421-A1 | Conjugate comprising an antinociceptive agent covalently bonded to a blood component | OPRK1, OPRL1, OGFR | CSNK2A2 2436/4885CSNK2B 2654/4885CSNK2A1 2476/4885 |
| US-20030170250-A1 | Local delivery of long lasting therapeutic agents | VEGFA, MMP8, MMP1 | CSNK2A2 3130/4885CSNK2B 3404/4885CSNK2A1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.